In addition, we found 19 tumors (31.66%) with simultaneous mutations in two genes and five tumors with concomitant mutations in KRAS, NRAS, and BRAF genes, and one tumor with concurrent mutations in KRAS, NRAS, and EGFR genes with AF‰ ≥ 1. The gene discussed is KRAS; the disease is neoplasm.